Table 1.
Placebo group (n = 43) | Phylloquinone group (n = 39) | P value | |
---|---|---|---|
Age (y) | 40.09 ± 4.65 | 40.25 ± 5.32 | 0.88* |
Weight (kg) at study baseline | 71.09 ± 6.59 | 71.21 ± 6.47 | 0.93* |
Weight (kg) at end of trial | 71 ± 6.76 | 70.72 ± 6.39 | 0.84* |
BMI (18.5-24.9 kg/m2) at study baseline | 1(2.3%) | 3(7.7%) | 0.342** |
BMI (18.5-24.9 kg/m2) at the end of trial | 2(4.7%) | 5(12.8%) | 0.249** |
BMI (25–29.9 kg/m2) ) at study baseline | 42(97.7%) | 36(92.3%) | 0.342** |
BMI (25–29.9 kg/m2) at the end of trial | 41(95.3%) | 34(87.2%) | 0.249** |
FM (%) at study baseline | 38.55 ± 3.99 | 38.77 ± 3.86 | 0.79* |
FM (%) at end of trial | 38.57 ± 4.10 | 38.46 ± 4.05 | 0.90* |
HbA1C (%) at study baseline | 5.91 ± 0.49 | 5.81 ± 0.64 | 0.42* |
All values are means ± SDs.
*Obtained from independent-samples t test.
**Obtained from chi-square test.